The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Moderna said its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

Moderna had been awarded over $750 million to develop a vaccine against bird flu, which has been circulating in farm animals and sickening people.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...